Skip to main content
SpringerLink
Log in

The Expanding Role of Pharmacy and Therapeutics Committees

The 1990s and Beyond

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Traditionally, pharmacy and therapeutics (P&T) committees have been responsible for overseeing the drug use process, using formulary systems to control drug costs. Primarily, these committees act in an advisory capacity as policy-recommending bodies within healthcare systems, for the specific purpose of promoting rational drug therapy. Methodologies utilised by these committees include drug use evaluation, medical staff education, continuous quality improvement, formulary restriction and therapeutic interchange. Future roles of P&T committees will include the evaluation of clinical outcomes information, including quality-of-life issues, to establish policies governing the use of drugs at all levels and in all types of healthcare.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Society of Hospital Pharmacists. Lilly survey shows sharp increase in hospital pharmacies’ purchases. Am J Hosp Pharm 1992: 49: 745–746

    Google Scholar 

  2. American Society of Hospital Pharmacists ASHP). Practice standards of ASHP 1991–1992. Bethesda (MD): American Society of Hospital Pharmacists, 1991

    Google Scholar 

  3. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Publishing Servicers 1995

    Google Scholar 

  4. Nash DB. Catalano ML. Wordell CJ. The formulary decision-making process in a US academic medical centre. PharmacoEconomics 1993: (1): 22–35

    Article  Google Scholar 

  5. Joint Commission on Accreditation of Hospitals (JCAH). Accreditation manual for hospitals. Chicago: JCAH. 1965

    Google Scholar 

  6. Lipman AC. A new formulary statement and formulary service [editorial]. Hosp Formul 1983; 18: 771

    PubMed  CAS  Google Scholar 

  7. Hunter WJ, Davis RB. Formulary review and DUE of oral ketorolac. P&T 1994 Oct: 19: 953, 957-8. 962, 965

    Google Scholar 

  8. Taylor G. Blondel-Hill E, Kibsey P, et al. Containing cefoxitin costs through a program to curtail use in surgical prophylaxis. Can J Infect Dis 1993; 4: 275–278

    PubMed  CAS  Google Scholar 

  9. Cimino MA. Rotstein CM, Moser JM. Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients. Ann Pharmacother 1994; 28: 105–111

    PubMed  CAS  Google Scholar 

  10. Moody SB, Sveska K.J. Fluconazole dosing in renal impairment: a drug usage evaluation. Hosp Formul 1993; 28: 499–502

    PubMed  CAS  Google Scholar 

  11. Hayman JN, Crane VS. Multi disciplinary task force for controlling drug expenses. Am J Hosp Pharm 1993; 50: 2343–2347

    PubMed  CAS  Google Scholar 

  12. Schlicht JR, Porter CK, Weber DR. et al. Drug use evaluations of intravenous ciprofloxacin: changing prescribing practices through education. P&T 1994 Dec; 19: 1120, 1123-4, 1126-7

    Google Scholar 

  13. Wade WE. McCall CY. Educational effort and CQI program improves ordering of serum digoxin levels. Hosp Formul 1994; 29: 657–659

    PubMed  CAS  Google Scholar 

  14. Successful conversion from lovastatin to pravastatin in a staff model HMO. Hosp Formul 1994; 29: 104-5

  15. Wade WE. McCall CY. How a CQI program improved aminoglycoside use in a community hospital. Hosp Formul 1995; 30: 114–116

    PubMed  CAS  Google Scholar 

  16. Matanin D, Cutrell D. A continuous quality improvement program for phenytoin IV. Hosp Formul 1994; 29: 212–215

    PubMed  CAS  Google Scholar 

  17. Gianarkis DG. Ketorolac formulary restriction and usage evaluation [letter]. Drug Intell Clin Pharm 1991; 25: 1399

    CAS  Google Scholar 

  18. Drexler PG, Lambdin CS. Reducing outpatient costs of non-steroidal antiinflammatory drugs at a department of veterans affairs teaching hospital. J Pharm Technol 1993; 9: 10–13

    PubMed  CAS  Google Scholar 

  19. Okpara AU. Enforcing an antimicrobial restriction policy through amikacin DUE. P&T 1994 Apr; 19: 375–376, 379-83

    Google Scholar 

  20. Keith MR, Cason DM, Helling DK. Antiulcer prescribing program in a state correctional swem. Ann Pharmacother 1994; 28: 792–795

    PubMed  CAS  Google Scholar 

  21. Maswoswe JJ, Okpara A. Enforcing a policy for restricting antimicrobial drug use. Am J Health-System Pharm 1995; 52: 1433–1435

    CAS  Google Scholar 

  22. Ament PW. Matanin D, Cutrell DK. Avoiding cost through pharmacy-managed interchange. P&T 1994 Sep; 19: 885–886, 891-2

    Google Scholar 

  23. Korman L. Borysiuk L. Replacing lovastatin with pravastatin: effect on serum lipids and costs. Am J Health-System Pharm 1995; 52: 1078–1082

    CAS  Google Scholar 

  24. Frighetto L. Nickoloff D. Jewesson P. Antibiotic therapeutic interchange program: six years of experience. Hosp Formul 1995; 30: 92–93, 97-8, 100, 103-5

    PubMed  CAS  Google Scholar 

  25. Ekedahl A, Petersson B. Eklund P. et al. Prescribing patterns and drug costs: effects of formulary recommendations and community pharmacist’s information campaigns. Int J Pharm Pract 1994 Jun; 2: 194–199

    Article  Google Scholar 

  26. Shepherd MD, Salzman RD. The formulary decision-making process in a health maintenance organisation setting. PharmacoEconomics 1994; (1): 29–38

    Article  Google Scholar 

  27. Spilker B. Use and abuse of pharmacoeconomic trials. Drug News Perspect 1994: 7 (6): 363–369

    Google Scholar 

  28. Lee JT. Sanchez LA. Interpretation of cost-effective and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2622–2627

    PubMed  CAS  Google Scholar 

  29. Chase P, Bell J, Smith P, et al. Redesign of the P & T committee around continuous quality improvement principles. P&T 1995 Jan; 20: 25–26, 29-30, 32, 34, 37-8, 40

    Google Scholar 

  30. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992; 49: 1741–1747

    PubMed  CAS  Google Scholar 

  31. Sanchez LA. Pharmacoeconomic principles and methods: conducting pharmacoeconomic evaluations in a hospital setting. Hosp Pharm 1995; 30 (5): 412–428

    PubMed  CAS  Google Scholar 

  32. Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research. PharmacoEconomics 1995; 8 (2): 169–174

    Article  PubMed  CAS  Google Scholar 

  33. Coons SJ, Kaplan RM. Quality of life assessment: understanding its use as an outcome measure. Hosp Formul 1993; 28: 486–498

    PubMed  CAS  Google Scholar 

  34. Mackeigan LD, Pathak DS. Overview of health-related quality-of-life measures. Am J Hosp Pharm 1992; 49 (2): 236–245

    Google Scholar 

  35. Jaeschke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. PharmacoEconomics 1992; 1: 84–93

    Article  PubMed  CAS  Google Scholar 

  36. Sanchez LA. Application of health-related quality of life to hospital pharmacy practice. Hosp Pharm 1995; 30 (10): 928–930

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, College of Pharmacy, University of Georgia, Athens, Georgia, 30602, USA

    William E. Wade & William J. Spruill

  2. Clinical Pharmacy Program, Medical College of Georgia, Augusta, Georgia, USA

    A. Thomas Taylor, R. Leon Longe & David W. Hawkins

Authors
  1. William E. Wade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. Spruill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Thomas Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Leon Longe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David W. Hawkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William E. Wade.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wade, W.E., Spruill, W.J., Taylor, A.T. et al. The Expanding Role of Pharmacy and Therapeutics Committees. Pharmacoeconomics 10, 123–128 (1996). https://doi.org/10.2165/00019053-199610020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610020-00004

Keywords

Search

Navigation